Lixisenatide
- Generic Name
- Lixisenatide
- Brand Names
- Adlyxin Starter Kit, Lyxumia, Soliqua
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 320367-13-3
- Unique Ingredient Identifier
- 74O62BB01U
- Background
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
- Indication
Lixisenatide is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type II diabetes mellitus. It is also available in combination with insulin glargine for the same indication.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 156
- Registration Number
- NCT03439943
- Locations
- 🇫🇷
University Hospital of Besancon, Besancon, France
🇫🇷University Hospital of Caen, Caen, France
🇫🇷University Hospital of Rouen, Rouen, France
Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog
- Conditions
- Interventions
- First Posted Date
- 2016-05-10
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Laniado Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT02767596
- Locations
- 🇮🇱
Bildirici Diabetes Center, Laniado Hospital, Netanya, Israel
Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT02745470
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects
- Conditions
- Interventions
- First Posted Date
- 2015-12-28
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- University Hospital, Gentofte, Copenhagen
- Target Recruit Count
- 24
- Registration Number
- NCT02640118
Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2015-10-29
- Lead Sponsor
- Royal Adelaide Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT02308254
- Locations
- 🇦🇺
Discipline of Medicine, Royal Adelaide Hospital, Adelaide, South Australia, Australia
Effect of LIXIsenatide on the Renal System
- Conditions
- Interventions
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2016-04-29
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 40
- Registration Number
- NCT02276196
- Locations
- 🇳🇱
VU Universtiy Medical Center, Amsterdam, Netherlands
Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Profil Institut für Stoffwechselforschung GmbH
- Target Recruit Count
- 109
- Registration Number
- NCT02231658
- Locations
- 🇩🇪
St. Josef-Hospital, Universitätsklinik, Bochum, Germany
🇩🇪Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin
- Conditions
- Interventions
- First Posted Date
- 2014-06-20
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 10
- Registration Number
- NCT02168491
- Locations
- 🇦🇹
Medical University Of Vienna, Department of Internal Medicine III, Vienna, Austria
Study on Lixisenatide and Counterregulation to Hypoglycemia
- First Posted Date
- 2013-12-25
- Last Posted Date
- 2015-12-15
- Lead Sponsor
- Lund University
- Target Recruit Count
- 18
- Registration Number
- NCT02020629
- Locations
- 🇸🇪
Clinical Research Department, Malmö, Sweden
Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-10-31
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 404
- Registration Number
- NCT01973231
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Taunton, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.